The Rising Demand for High-Potency ADC Payloads: Why the Supply Chain Is Being Reshaped in 2025 Antibody–drug conjugates (ADCs) continue to reshape the oncology pipeline, driven by the pursuit of payloads that can deliver stronger potency, improved tumor selectivity, and reduced systemic toxicity. Although more than a decade has passed since the approval of the first ADC, payload development remains one of the fastest-moving components of the field. With growing interest in high-DAR...
0 Compartilhamentos
37 Visualizações